Recently, the Tagoliticimab Injection (trade name: 科泰莱) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is approved for marketing by China NMPA. Indications: This product is indicated as monotherapy for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have failed to respond to second-line and later chemotherapy.

Tagitanlimab Injection is a humanized IgG1κ subtype monoclonal antibody that specifically binds to programmed cell death ligand-1 (PD-L1), blocking its interaction with programmed cell death receptor-1 (PD-1). As a result, it can relieve the inhibitory effect of tumor cells on T cells through the PD-1/PD-L1 pathway, enabling immune cells to resume their anti-tumor cellular immune function. The marketing of this drug provides a new treatment option for patients with nasopharyngeal carcinoma.